ANIP — ANI Pharmaceuticals, Inc. stock price, charts and financials

NASDAQ·Healthcare·Drug Manufacturers - Specialty & Generic·USA

Latest market price

76.14

+0.75+0.99%

Overview Short InterestFilings

ANIPQT53ANI Pharmaceuticals, Inc.·NASDAQ

Overview Short InterestFilings

76.14+0.99%

Loading chart...

Signal & projected range

Insider selling clusterHistorical pattern — not a prediction

Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)

Horizon

Unlock the projected rangeSee where this setup landed historically — with Premium.

Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →

PRGO+0.59%$13.56 TRLV-4.98%$11.07 ETON-2.75%$55.50 ALVO+9.93%$5.87 BHC+0.35%$5.67 PAHC+0.32%$34.56 HCM-1.09%$13.67 CRON-0.59%$3.35

Snapshot

Index	-	P/E	15.76	EPS (ttm)	4.83	Insider Own	24.26%	Shs Outstand	22.73M	Perf Week	8.48%

Market Cap	1.73B	Forward P/E	7.26	EPS next Y	10.48	Insider Trans	-1.95%	Shs Float	19.42M	Perf Month	-2.41%

Enterprise Value	1.70B	PEG	0.01	EPS next Q	2.12	Inst Own	-	Short Float	17.33%	Perf Quarter	-4.21%

Income	113.73M	P/S	1.77	EPS this Y	100.60%	Inst Trans	-	Short Ratio	9.86	Perf Half Y	1.76%

Sales	978.40M	P/B	2.70	EPS next Y	12.89%	ROA	7.08%	Short Interest	3.36M	Perf YTD	-3.55%

Book/sh	-	P/C	8.50	EPS next 5Y	10.80%	ROE	19.19%	52W High	98.55 -22.74%	Perf Year	-20.16%

Cash/sh	-	P/FCF	10.86	EPS past 3/5Y	-	ROIC	9.26%	52W Low	69.58 9.43%	Perf 3Y	21.20%

Dividend Est.	-	EV/EBITDA	6.65	Sales past 3/5Y	40.85% 33.53%	Gross Margin	65.23%	Volatility	3.01% 2.63%	Perf 5Y	177.48%

Dividend TTM	-	EV/Sales	1.74	EPS Y/Y TTM	545.19%	Oper. Margin	15.35%	ATR (14)	2.13	Perf 10Y	23.26%

Dividend Ex-Date	-	Quick Ratio	2.41	Sales Y/Y TTM	59.28%	Profit Margin	10.82%	RSI (14)	57.08	Recom	2.40

Dividend Gr. 3/5Y	-	Current Ratio	2.91	EPS Q/Q	22.78%	SMA20	4.46%	Beta	0.49	Target Price	104.33

Payout	0.33%	Debt/Eq	0.55	Sales Q/Q	26.07%	SMA50	-0.34%	Rel Volume	3.00	Prev Close	75.39

Employees	970	LT Debt/Eq	0.57	Earnings	Nov 06	SMA200	-3.48%	Avg Volume	368.45K	Price	76.14

IPO Date	May 05, 2000	Option/Short	Yes / Yes	EPS/Sales Surpr.	8.19% 2.27%	Net Debt/EBITDA	-0.12	Volume	1,104,255	Change	0.99%

Analyst Ratings

Date	Action	Analyst	Rating	Target
Sep-09-26	Initiated	Leerink	Outperform	$104
Aug-10-26	Reiterated	Guggenheim	Buy	$124 → $119
Aug-10-26	Reiterated	Canaccord Genuity	Hold	$91 → $90
Jul-16-26	Initiated	Canaccord	Hold	$91
Jan-16-26	Reiterated	Guggenheim	Buy	$114 → $124
Oct-09-25	Reiterated	Truist Securities	Hold	$60 → $90
Sep-17-25	Reiterated	HC Wainwright & Co.	Buy	$94 → $121
Sep-08-25	Reiterated	Guggenheim	Buy	$86 → $114
Aug-08-25	Reiterated	Piper Sandler		$80 → $94
Mar-05-25	Reiterated	Guggenheim	Buy	$86

Latest News· Times ET

Sep-14-26

Sep-14-2606:31AM

ANI Pharmaceuticals, Inc. (ANIP) Presents at Morgan Stanley 24th Annual Global Healthcare Conference TranscriptSeekingAlpha

Sep-10-26

Sep-10-2611:45PM

Contrasting ANI Pharmaceuticals (NASDAQ:ANIP) and Cumberland Pharmaceuticals (NASDAQ:CPIX)defenseworld.net

Sep-04-26

Sep-04-2606:14PM

ANI Pharmaceuticals (ANIP) Appoints Henry Gosebruch To Its BoardYahoo

Sep-03-26

Sep-03-2602:55AM

ANI Pharmaceuticals to Present at September Investor Conferencesglobenewswire.com

Aug-24-26

Aug-24-2602:55AM

ANI Pharmaceuticals Appoints Henry Gosebruch to Board of Directorsglobenewswire.com

Aug-19-26

Aug-19-2611:18PM

Aurora Investment Counsel Takes Position in ANI Pharmaceuticals, Inc. $ANIPdefenseworld.net

Aug-14-26

Aug-14-2610:17AM

ANIP's Cortrophin Guidance Cut Raises the Bar for Second-Half Growthzacks.com

10:17AM

Should You Buy ANIP as Low Valuation Meets Cortrophin Execution Risk?zacks.com

Aug-10-26

Aug-10-2610:06AM

ANIP Tops Q2 Earnings, Stock Down on Cortrophin Sales View Cutzacks.com

06:07AM

Guggenheim Maintains Buy on ANI Pharmaceuticals, Lowers Price Target to $119Benzinga

Aug-07-26

Aug-07-2610:44AM

ANI Pharmaceuticals, Inc. (ANIP) Q2 2026 Earnings Call Transcriptseekingalpha.com

06:31AM

Compared to Estimates, ANI (ANIP) Q2 Earnings: A Look at Key Metricszacks.com

06:06AM

ANI Pharmaceuticals Q2 Earnings Call Highlightsmarketbeat.com

05:06AM

ANI Pharmaceuticals (ANIP) Q2 Earnings and Revenues Beat Estimateszacks.com

02:50AM

ANI Pharmaceuticals Reports Record Second Quarter 2026 Financial Resultsglobenewswire.com

Company

ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and potent products. The company serves its products to national wholesalers, specialty pharmacies, retail pharmacy chains, distributors, mail order houses, group purchasing organizations, and hospitals and healthcare providers. ANI Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Baudette, Minnesota.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements

DataTimeframe

Line Item (USD, M)	TTM —	FY 2025 12/31/2025	FY 2024 12/31/2024	FY 2023 12/31/2023	FY 2022 12/31/2022	FY 2021 12/31/2021	FY 2020 12/31/2020	FY 2019 12/31/2019	FY 2018 12/31/2018
Total Revenue	978	883	614	—	—	—	—	—	—
Cost of Goods Sold Incl. D&A	341	433	250	—	—	—	—	—	—
Gross Profit	639	451	364	—	—	—	—	—	—
Selling, General and Administrative Excl. Other	326	318	250	—	—	—	—	—	—
Research and Development	50	52	45	—	—	—	—	—	—
Other Operating Expense	111	-1	69	—	—	—	—	—	—
Operating Income	150	81	1	—	—	—	—	—	—
Interest Expense	28	20	18	—	—	—	—	—	—
Unusual Expense	—	—	—	—	—	—	—	—	—
Non-Operating Income (Expense)	20	35	-5	—	—	—	—	—	—
Net Income Before Taxes	142	96	-22	—	—	—	—	—	—
Income Taxes	34	17	-4	—	—	—	—	—	—
Consolidated Net Income	105	78	-19	—	—	—	—	—	—
Net Income From Continuing Operations	108	78	-19	—	—	—	—	—	—
Net Income	105	78	-19	—	—	—	—	—	—
EPS (Recurring)	4.83	3.50	-1.04	—	—	—	—	—	—
EPS (Basic, Before Extraordinaries)	4.83	3.50	-1.04	—	—	—	—	—	—
EPS (Diluted)	4.63	3.32	-1.04	—	—	—	—	—	—
EBITDA	255	207	63	—	—	—	—	—	—
Other After Tax Adjustments	—	—	—	—	—	—	—	—	—
Stock Option Compensation Expense	—	—	—	—	—	—	—	—	—
Price To Earnings Ratio	16.44	23.78	—	—	—	—	—	—	—
Price To Sales Ratio	1.63	1.79	1.71	—	—	—	—	—	—
Gross Margin	65.34	51.08	59.28	—	—	—	—	—	—
Operating Margin	15.34	9.17	0.16	—	—	—	—	—	—
Net Margin	10.74	8.83	-3.09	—	—	—	—	—	—
Shares Outstanding	21	20	19	—	—	—	—	—	—
Market Capitalization	1,599	1,579	1,050	—	—	—	—	—	—
Operating Lease Expense	—	—	—	—	—	—	—	—	—

Unlock full historical data

See years of past statements with Premium.

Unlock with Premium

Insider Trading Volume

Insider Trading

Insider	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Lalwani Nikhil	PRESIDENT & CEO	Sep 15 '26	Sale	71.00	5,400	383,400	339,089	Sep 16
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Sep 14 '26	Sale	70.79	500	35,395	73,924	Sep 14
Thoma Jeanne	Director	Sep 11 '26	Sale	71.53	1,000	71,530	26,762	Sep 14
CAREY STEPHEN P.	SVP & CFO	Aug 31 '26	Sale	72.80	2,850	207,480	171,843	Sep 01
Lalwani Nikhil	PRESIDENT & CEO	Aug 25 '26	Sale	74.30	5,400	401,220	344,489	Aug 26
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Aug 13 '26	Sale	75.48	500	37,740	74,424	Aug 13
Gutwerg Ori	SVP, GENERICS	Aug 10 '26	Sale	77.00	3,162	243,474	75,534	Aug 11
CAREY STEPHEN P.	SVP & CFO	Jul 29 '26	Sale	81.36	2,850	231,876	174,693	Jul 30
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jul 13 '26	Sale	81.84	500	40,920	77,390	Jul 14
CAREY STEPHEN P.	SVP & CFO	Jul 02 '26	Sale	86.00	3,313	284,918	177,543	Jul 06
CAREY STEPHEN P.	SVP & CFO	Jul 02 '26	Option Exercise	49.51	3,313	164,027	180,856	Jul 06
CAREY STEPHEN P.	SVP & CFO	Jun 29 '26	Sale	84.12	2,850	239,742	177,543	Jun 30
Cook Meredith	SR. VP, GENERAL COUNSEL & SEC.	Jun 12 '26	Sale	82.03	500	41,015	77,890	Jun 15
HAUGHEY THOMAS	Director	Jun 08 '26	Sale	80.88	2,000	161,760	38,878	Jun 10
CAREY STEPHEN P.	SVP & CFO	Jun 05 '26	Option Exercise	49.51	3,312	163,977	183,705	Jun 09

open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR

QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.